NASDAQ · BMEA
Biomea Fusion, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BMEA: Nov 3, 2026
Biomea Fusion, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.27.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.18 | $-0.17 | $-0.19 | 4 |
| Dec 2026 | $-0.18 | $-0.16 | $-0.20 | 4 |
| Mar 2027 | $-0.17 | $-0.14 | $-0.20 | 2 |
| Jun 2027 | $-0.19 | $-0.17 | $-0.21 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Zacks- RTTNews · Oct 16, 10:55 AM EDTWeekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) – This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.
- RTTNews · Oct 13, 10:34 PM EDTBiomea Reports Phase 1 Weight-Loss Data For Oral GLP-1 Candidate BMF-650; Shares Fall(RTTNews) – Biomea Fusion Inc. (BMEA) reported Phase 1 results for BMF-650, its investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed for obesity and metabolic disorders.
- MarketBeat · Oct 13, 9:02 PM EDTBiomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 StudyAre (More) Big Gains Ahead for This Small Cap Biotech Stock?Biomea Fusion (NASDAQ:BMEA) reported top-line results from a Phase Ib multiple ascending-dose study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist being developed for weight management. The com
- RTTNews · Oct 13, 6:02 AM EDTBiomea Shares Rise Ahead Of Phase I Data Readout For Obesity Drug BMF-650(RTTNews) – Biomea Fusion, Inc. (BMEA) is scheduled to release Phase I GLP-131 data for its investigational obesity candidate BMF-650 today, October 13, 2026, with shares rising 6.44% to $1.44 in premarket trading ahead of the readout.
- RTTNews · Sep 23, 11:50 AM EDTBiomea Fusion Terminates Planned Securities Offering; Shares Slide(RTTNews) – Biomea Fusion, Inc. (BMEA) announced that it has terminated its proposed public offering of securities, which was previously announced on September 22.
- RTTNews · Sep 23, 1:57 AM EDTBiomea Fusion Launches Public Offering; Stock Down(RTTNews) – Biomea Fusion, Inc. (BMEA) a clinical-stage company focused on diabetes and obesity announced an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common shares.
- Zacks · Sep 4, 9:55 AM EDTAfter Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is BrightGood things could be on the horizon when a stock experiences a golden cross event. How should investors react?
- Zacks · Sep 1, 9:40 AM EDTAre Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?Here is how Brookdale Senior Living (BKD) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.
- RTTNews · Aug 24, 8:06 AM EDTBiomea Completes Enrollment In Phase 2 COVALENT-211 Diabetes Trial Of Icovamenib; Shares Rise(RTTNews) – Biomea Fusion, Inc. (BMEA), a clinical-stage company focused on diabetes and obesity medicines, announced the completion of enrollment in the phase 2 COVALENT-211 evaluating icovamenib in patients with insulin-deficient Type 2 Diabetes or T2D.
- RTTNews · Aug 6, 4:06 AM EDTBioMea Q2 Loss Shrinks; Data From Phase 2 Trials For Icovamenib In Diabetes Expected In '27(RTTNews) – Biomea Fusion, Inc. (BMEA) recorded a narrowed loss for the second quarter ended June 30, 2026, attributable to lower operating expenses. The biotech company also provided various pipeline updates.
- RTTNews · Jun 8, 7:54 AM EDTBiomea Presents Promising Phase 2 Data For Icovamenib In Diabetes; Advances Phase 1 For BMF-650(RTTNews) – Biomea Fusion Inc. (BMEA), a clinical-stage diabetes and obesity company, on Friday announced new translational and Phase 2 data for Icovamenib in treating type-1 and type -2 diabetes. Data was presented at the scientific sessions of the American Diabetes Association
- RTTNews · May 12, 2:18 AM EDTBiomea Reports Q1 Loss Of $12 Mln; Phase 2 Diabetes Study Results Due In Q4(RTTNews) – Biomea Fusion Inc. (BMEA), a clinical-stage diabetes and obesity company, reported on Monday its first-quarter financial results and provided updates across its diabetes and obesity drug pipeline.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Biomea Fusion, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.